|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0183683,
umls-concept:C0205179,
umls-concept:C0242792,
umls-concept:C0344211,
umls-concept:C0439590,
umls-concept:C0439859,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1328050,
umls-concept:C1514474,
umls-concept:C1521721
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1995-9-11
|
|
pubmed:abstractText |
With a median observation time of 50 months from transplant, 13 (22%) of 62 women with metastatic breast cancer treated with high-dose chemotherapy at the Dana-Farber Cancer Institute (DFCI)/Beth Israel Hospital (BIH) remain progression-free. This study determined factors prognostic for prolonged progression-free survival (PFS).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2043-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7636547-Adolescent,
pubmed-meshheading:7636547-Adult,
pubmed-meshheading:7636547-Age Factors,
pubmed-meshheading:7636547-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7636547-Bone Marrow Transplantation,
pubmed-meshheading:7636547-Breast Neoplasms,
pubmed-meshheading:7636547-Carboplatin,
pubmed-meshheading:7636547-Combined Modality Therapy,
pubmed-meshheading:7636547-Cyclophosphamide,
pubmed-meshheading:7636547-Disease-Free Survival,
pubmed-meshheading:7636547-Female,
pubmed-meshheading:7636547-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:7636547-Humans,
pubmed-meshheading:7636547-Middle Aged,
pubmed-meshheading:7636547-Multivariate Analysis,
pubmed-meshheading:7636547-Neoplasm Metastasis,
pubmed-meshheading:7636547-Prognosis,
pubmed-meshheading:7636547-Proportional Hazards Models,
pubmed-meshheading:7636547-Remission Induction,
pubmed-meshheading:7636547-Thiotepa,
pubmed-meshheading:7636547-Transplantation, Autologous
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
